Tag: vaccination

Categories : COVIDTags :

US Health Workers’ Vaccine Hesitancy Is Cause for Concern

On By ModernMedia

Health care workers in various parts of the United States are showing extraordinarily high rates of COVID vaccine hesitancy: 20% to 40% of front line workers in Los Angeles, and 60% of nursing home workers said they would refuse to take the vaccine. This has generated great concern along with some instances of shaming, but failing to address these worries is potentially going to worsen the progression of the pandemic.

Fortunately, national surveys show that vaccine hesitancy is decreasing with some 60% of Americans now intending to receive a vaccine, but the high numbers among healthcare workers demands attention. Speaking to the Guardian, Dr Whitney Robinson, an epidemiologist at the University of North Carolina, said that if this is not addressed, “It could mean after all this work, after all this sacrifice, we could still be seeing outbreaks for years, not just 2021, maybe 2022, maybe 2023.”

In Atlanta, while hundreds of healthcare workers were on the list for vaccines, the doses were literally “sitting in the freezers” because no-one would take them.In one survey, up to 55% of New York firefighters said would not take the vaccines, so the Uniformed Firefighters Association president put together a 50 minute video with a virologist friend, addressing their concerns. Subsequent calls from firefighters showed the video had helped to change minds and increase vaccination numbers.

The concerns are varied. Some are concerned about possible side effects and long term consequences, or have read misinformation online. Others are worried about the effect it will have on pregnant and breastfeeding women. Still others believe that having the vaccine is unnecessary after having recovered it, as they have the antibodies in their system. A lot of the distrust may be from minority groups’ deep-rooted distrust of large-scale health programs such as vaccinations, according to Dr Nikhila Juvvadi, the chief clinical officer at Loretto hospital in Chicago. Many specifically mentioned the Tuskegee Study, where federal health officials studied African-American men with sexually transmitted diseases which were deliberately not treated.

“I’ve heard Tuskegee more times than I can count in the past month – and, you know, it’s a valid, valid concern,” said Juvvadi.
However, she said that individual conversations were effective in helping alleviate concerns about the vaccines.

Source: The Guardian

Categories : COVID UncategorizedTags :

Medical Aid Schemes to Share Cost of Nationwide Vaccination

On By ModernMedia

As arrangements are being made to pay for the COVID vaccination programme for South Africa, medical aid schemes are expected to contribute to the cost towards ensuring at least 67% of the population receives a vaccine, which is the minimum number to establish herd immunity.

Across South Africa, there are some 9 million medical aid beneficiaries, making up some 16% of the population and who collectively spent R186 billion last year on healthcare. The total cost of providing sufficient vaccines for the South African population is thought to range from R5 billion to R20 billion, depending on whether the vaccine is simply bought for the commercial price or whether the distribution and administration costs are factored in as well.

Discussions into paying for the mass vaccinations have suggested that mass-employers, such as mines, ought to contribute  This week, the Council for Medical Schemes (CMS) confirmed that vaccination would be a minimum prescribed benefit, so this will not be paid for out of medical savings.”The CMS acknowledges that there may be an additional cost burden to medical schemes for the provision of the vaccine, but this is not expected to be prohibitively high,” the body said. “In addition, industry associations have assured the CMS that vaccine costs can be absorbed by most medical schemes.”

South Africa’s vaccine source is not yet clear, although President Cyril Ramaphosa has hinted that Canada may share its excess vaccine stock. Canada currently has enough vaccine pre-purchase agreements to vaccinate its population five times over.

Source: Business Insider

Categories : UncategorizedTags :

COVID Vaccinations for Those Who Have Recovered?

On By ModernMedia

As mass COVID vaccination programmes get underway around the world, an Op-Ed in MedPage Today debates whether people who have recovered from COVID should receive a vaccination.

Even given that there are over 200 vaccines in development, with a typical 7% success rate for vaccines, the 80-95% efficacy reported for the various vaccines being administered and the numbers of successful vaccines is a great outcome. Despite this, considering the great difficulty in producing enough vaccines for the world, should perhaps people who recovered from COVID not receive the vaccine, as they now are protected by a level of immunity?

The perspectives of immunology and bioethics indicate why such a person should also be vaccinated. There would be no difference in vaccinating a person who has had COVID to a person who has recovered then been re-exposed or re-infected. In both cases, a rapid immune response will be mounted in either individual, and either will be asymptomatic or present with mild, manageable symptoms. A re-exposure to the SARS-CoV-2 virus or receiving a vaccine might strengthen such a person’s immunity to future COVID infections.The immune system maintains an immunological library in our lymphatic system which stores memory lymphocytes (B cells) that respond to any past infection encountered by an individual. On a second or third exposure to a particular pathogen, these B cells are mobilised and rapidly prevent re-infection. Vaccines are designed to mimic a viral exposure without eliciting a dangerous viral infection. B cells don’t cause illness, only prompting the immune system, mitigating the infection.
Furthermore, vaccinations confer additional protections beyond just that of the disease which they are meant to protect against. There are abundant data that shows that vaccinations against measles, influenza, or TB generate lymphocytes that even help protect vaccinated individuals against COVID. In one theory on why young children do not present with severe COVID, standard childhood vaccinations are believed to  boost their overall level of immunity.

With so many factors complicating vaccine administration, it is best not to add yet another wrinkle, and there is also no information to suggest that vaccinating someone who has recovered from a virus will cause harmful effects. On the contrary, re-exposure to a virus or a subsequent vaccination against that virus could generate superior lymphocytes to combat further infection.

Source:MedPage Today

Categories : UncategorizedTags :

Aspen Shifts to SA Production of COVID Vaccines

On By ModernMedia

Aspen Pharmacare has secured a deal to manufacture the Johnson & Johnson COVID vaccine, in an effort to adapt to the pharmaceutical market. 

Elective surgeries being deferred due to the pandemic has reduced demand for certain medications, and the company withheld dividends for the second year running in September. However, the company does produce some medications which are currently in demand due to COVID.

Dexamethasone, one of the medications Aspen has the rights to produce, is a key treatment for COVID patients, which according to a study done in June, reduces mortality by 30%. Colchicine is another medication used to treat COVID, normally used for gout.

Tavros Nicolaou, a senior Aspen executive, said in an interview: “In February, we looked at how we best respond to this looming disaster facing us and we split it into three buckets — what we can do at a therapeutic level, what can we do at a vaccine level and what can we do to generally help society.” This positioned them “globally as a company that had a multifaceted response to this pandemic.”

The pharmaceuticals company has invested R3 billion in a Port Elizabeth plant to manufacture the Johnson & Johnson COVID vaccine at a rate of 300 million per year, which will help supply the rest of Africa. The need for local COVID vaccines may come sooner rather than later.

Despite peaking in July, the country’s COVID pandemic is not yet over with at least two provinces seeing increases in cases again, while on the horizon a second surge is expected in January.

Source: Moneyweb

Categories : UncategorizedTags :

UNICEF Calls for Urgent Action to Avoid Polio and Measles Epidemics

On By ModernMedia

UNICEF and the World Health Organization issued a press release today calling for a major effort to avert impending epidemics of both polio and measles resulting from disruption caused by COVID.

The organisations estimate that US$655 million (US$400 million for polio and US$255 million for measles) is needed to address immunity gaps that are opening up for these deadly and debilitating diseases.

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said, “COVID-19 has had a devastating effect on health services and in particular immunization services, worldwide. But unlike with COVID, we have the tools and knowledge to stop diseases such as polio and measles. What we need are the resources and commitments to put these tools and knowledge into action. If we do that, children’s lives will be saved.”

Henrietta Fore, UNICEF Executive Director, added, “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against other diseases. Addressing the global COVID-19 pandemic is critical. However, other deadly diseases also threaten the lives of millions of children in some of the poorest areas of the world. That is why today we are urgently calling for global action from country leaders, donors and partners. We need additional financial resources to safely resume vaccination campaigns and prioritize immunization systems that are critical to protect children and avert other epidemics besides COVID-19.”

Gaps were already opening in measles coverage, with minor outbreaks even before the disruption of the COVID pandemic. Polio risks resurgence in Afghanistan, Pakistan and in under-immunised areas of Africa. To help address these challenges, a novel polio vaccine is being developed and a new response plan is being developed.

Categories : HIV Immune SystemTags :

HIV Vaccine Search is a Marathon

On By ModernMedia

While COVID vaccines have appeared in a record-breaking short time, an HIV vaccine is still yet to arrive – though not without good reasons, as The Daily Maverick reports.

Mitchell Warren, executive director of AVAC, a US-based HIV advocacy organisation explained: “There is still no conclusive research on what type of immune response an HIV vaccine should be trying to trigger.”

“With HIV, you’re trying to do better than nature,” continued Warren. “With a Covid-19 vaccine, the jab merely has to do what nature is doing already — in the form of an immune response — just faster. But with HIV, you’re trying to do better than nature because your body isn’t able to successfully fight off the virus.”

HIV mutates quite rapidly, to the point where there are now two distinct strains, HIV-1 and HIV-1, complicating the process. SARS-CoV-2 on the other hand uses a process called proofreading when it replicates, ensuring a lower rate of mutations.

There are currently three vaccines in development; HPX2008/HVTN 705: Imbokodo and HPX3002/HVTN 706: Mosaico both use adenoviruses to deliver protein fragments of the HIV virus to train the immune system to respond to it. The “Imbokodo” is being trialled with young women, and “Mosaico” is being trialled with transgender men and men who have sex with men, and expected to end in 2022 and 2024 respectively. 

The PrEPVacc vaccine uses DNA inserted into plasmids, which induce the body to produce the virus’ proteins, but not the virus itself. The two shots contain a cocktail of proteins and the plasmids to train the immune system. The trial is expected to end in 2023